XNASMRSN
Market cap85mUSD
Jan 10, Last price
0.69USD
1D
-46.75%
1Q
-64.86%
IPO
-94.88%
Name
Mersana Therapeutics Inc
Chart & Performance
P/E
—
P/S
2.32
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
38.20%
Rev. gr., 5y
28.32%
Revenues
37m
+38.65%
Net income
-172m
L-17.28%
CFO
-169m
L+242.12%
Earnings
Feb 26, 2025
Profile
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 36,855 38.65% | 26,581 61,716.28% | |||||||
Cost of revenue | 356,081 | 231,275 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (319,226) | (204,694) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 3,328 | ||||||||
Tax Rate | |||||||||
NOPAT | (319,226) | (208,022) | |||||||
Net income | (171,670) -17.28% | (207,540) 22.66% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 93,539 | 3,461 | |||||||
BB yield | -34.72% | -0.63% | |||||||
| Debt | |||||||||
Debt current | 5,479 | 2,798 | |||||||
Long-term debt | 36,752 | 44,877 | |||||||
Deferred revenue | 97,167 | 117,043 | |||||||
Other long-term liabilities | 1,000 | 203 | |||||||
Net debt | (166,853) | (233,515) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (168,882) | (49,363) | |||||||
CAPEX | (2,168) | (2,197) | |||||||
Cash from investing activities | 119,883 | (152,716) | |||||||
Cash from financing activities | 94,675 | 153,017 | |||||||
FCF | (316,291) | (207,625) | |||||||
| Balance | |||||||||
Cash | 209,084 | 280,712 | |||||||
Long term investments | 478 | ||||||||
Excess cash | 207,241 | 279,861 | |||||||
Stockholders' equity | (826,338) | (654,832) | |||||||
Invested Capital | 994,240 | 900,437 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 116,113 | 93,654 | |||||||
Price | 2.32 -60.41% | 5.86 -5.79% | |||||||
Market cap | 269,382 -50.92% | 548,814 25.01% | |||||||
EV | 102,529 | 315,299 | |||||||
EBITDA | (317,709) | (203,767) | |||||||
EV/EBITDA | |||||||||
Interest | 4,073 | 3,328 | |||||||
Interest/NOPBT | |||||||||